title: Benchmark dose and the three Rs. Part I. Getting more information from the same number of animals.
abstract: Evaluating dose-response data using the Benchmark dose (BMD) approach rather than by the no observed adverse effect (NOAEL) approach implies a considerable step forward from the perspective of the Reduction, Replacement, and Refinement, three Rs, in particular the R of reduction: more information is obtained from the same number of animals, or, vice versa, similar information may be obtained from fewer animals. The first part of this twin paper focusses on the former, the second on the latter aspect. Regarding the former, the BMD approach provides more information from any given dose-response dataset in various ways. First, the BMDL (= BMD lower confidence bound) provides more information by its more explicit definition. Further, as compared to the NOAEL approach the BMD approach results in more statistical precision in the value of the point of departure (PoD), for deriving exposure limits. While part of the animals in the study do not directly contribute to the numerical value of a NOAEL, all animals are effectively used and do contribute to a BMDL. In addition, the BMD approach allows for combining similar datasets for the same chemical (e.g., both sexes) in a single analysis, which further increases precision. By combining a dose-response dataset with similar historical data for other chemicals, the precision can even be substantially increased. Further, the BMD approach results in more precise estimates for relative potency factors (RPFs, or TEFs). And finally, the BMD approach is not only more precise, it also allows for quantification of the precision in the BMD estimate, which is not possible in the NOAEL approach.
authors.affiliation: National Institute of Public Health and the Environment (RIVM), Bilthoven , The Netherlands.
authors.forename: Wout
authors.initials: W
authors.lastname: Slob
mesh_terms: D000818:Animals; D019985:Benchmarking; D004305:Dose-Response Relationship, Drug; D019055:No-Observed-Adverse-Effect Level
keywords: BMD approach; NOAEL approach; PROAST; combined analysis; dose–response analysis; precision; three Rs